| Community-Acquired Pneumonia

Baxdela vs Teflaro

Side-by-side clinical, coverage, and cost comparison for community-acquired pneumonia.

Deep comparison between: Baxdela vs Teflaro with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTeflaro has a higher rate of injection site reactions vs Baxdela based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Teflaro but not Baxdela, including UnitedHealthcare

Category

Baxdela

Teflaro

At A Glance

RouteIV infusion or Oral

FrequencyEvery 12 hours

ClassFluoroquinolone antibacterial

RouteIV infusion

FrequencyEvery 12 hours

ClassCephalosporin antibacterial

Indications

Acute bacterial skin and skin structure infection
Community-Acquired Pneumonia

Acute bacterial skin and skin structure infection
Community-Acquired Pneumonia

Dosing

Acute bacterial skin and skin structure infection 300 mg IV infusion every 12 hours over 60 minutes, or 450 mg orally every 12 hours, for 5-14 days; IV dose reduced to 200 mg every 12 hours in patients with eGFR 15-29 mL/min/1.73m2.

Community-Acquired Pneumonia 300 mg IV infusion every 12 hours over 60 minutes, or 450 mg orally every 12 hours, for 5-10 days; IV dose reduced to 200 mg every 12 hours in patients with eGFR 15-29 mL/min/1.73m2.

Acute bacterial skin and skin structure infection Adults: 600 mg IV every 12 hours over 5 to 60 minutes for 5-14 days; pediatric patients >=2 years (>33 kg): 400 mg every 8 hours or 600 mg every 12 hours; pediatric patients >=2 years (<=33 kg): 12 mg/kg every 8 hours; 2 months to <2 years: 8 mg/kg every 8 hours; neonates (gestational age >=34 weeks, postnatal age >=12 days) to <2 months: 6 mg/kg every 8 hours over 30 to 60 minutes.

Community-Acquired Pneumonia Adults: 600 mg IV every 12 hours over 5 to 60 minutes for 5-7 days; pediatric patients >=2 years (>33 kg): 400 mg every 8 hours or 600 mg every 12 hours; pediatric patients >=2 years (<=33 kg): 12 mg/kg every 8 hours; 2 months to <2 years: 8 mg/kg every 8 hours over 5 to 60 minutes for 5-14 days.

Contraindications

Known hypersensitivity to delafloxacin, any fluoroquinolone antibacterial, or any component of BAXDELA

Known serious hypersensitivity to ceftaroline or other members of the cephalosporin class

Drug Interactions

1299View drug interactions

1068View drug interactions

Adverse Reactions

Most common (>=2%) Nausea, diarrhea, headache, transaminase elevations, vomiting

Serious Tendinitis and tendon rupture, peripheral neuropathy, CNS effects, hypersensitivity reactions, Clostridioides difficile-associated diarrhea, blood glucose disturbances

Most common (>=2%) Diarrhea, nausea, rash, constipation, vomiting, increased transaminases, hypokalemia, phlebitis

Serious Hypersensitivity reactions, anaphylaxis, Clostridioides difficile-associated diarrhea, neurological adverse reactions (dizziness, convulsion), direct Coombs' test seroconversion

Postmarketing Agranulocytosis, leukopenia, eosinophilic pneumonia, encephalopathy, seizures

Pharmacology

Delafloxacin is a fluoroquinolone antibacterial that inhibits bacterial topoisomerase IV and DNA gyrase, enzymes required for bacterial DNA replication, transcription, repair, and recombination, exhibiting concentration-dependent bactericidal activity against gram-positive and gram-negative organisms.

Ceftaroline is a cephalosporin antibacterial that exerts bactericidal activity by binding to essential penicillin-binding proteins (PBPs), including PBP2a in S. aureus and PBP2x in S. pneumoniae, and has in vitro activity against both Gram-positive and Gram-negative bacteria.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Baxdela